Hims & Hers Health Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Hims & Hers Health Bundle
Visual. Strategic. Downloadable.
Curious where Hims & Hers Health’s products land — Stars, Cash Cows, Dogs or Question Marks? This preview teases the picture; buy the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word report plus an Excel summary. Skip the guesswork, act with clarity, and allocate capital where it actually moves the needle.
Stars
ED Rx subscriptions
ED treatments are Hims’ category leader with strong brand recall and heavy repeat use; Hims & Hers reported roughly $518M revenue in 2023 with ED a core driver. The U.S. ED prescription market exceeds $1.5B annually and continues growing as stigma falls and online access rises. CAC is high but subscription economics deliver payback in about 6–9 months, supporting continued investment to defend share and expand SKUs.
Hair loss Rx (finasteride + minoxidil)
Hair loss Rx (finasteride + minoxidil) is Hims & Hers Health’s flagship growth engine with a dominant DTC market share and a 2024 revenue run-rate near $500M, reflecting durable demand. The proven funnel yields manageably low churn and a solid LTV/CAC profile, supporting mid-teens category growth as younger demos enter. Continued promo and retail placement sustain visibility and conversion.
Owned telehealth + pharmacy fulfillment stack
Owned end-to-end virtual care plus in-house pharmacy is a durable moat: it shortens prescription turnaround, improves patient experience and captures fulfillment margin, supporting Hims & Hers’ unit economics. The global telehealth market reached about $62.5 billion in 2024, and as adoption expands, the integrated platform scales with demand. Ongoing capex to modernize fulfillment and telehealth tech is justified to protect margin and growth.
Brand-led DTC performance marketing
Hims & Hers, a top-of-mind DTC health brand, sits in the Stars quadrant, compounding returns as category demand grows; the company reported FY2023 revenue of 616.7 million. Creative testing, influencer partnerships and social channels keep CAC efficient, while scale delivers buying power and richer customer data—keep feeding the engine to sustain growth.
- Position: Star
- FY2023 revenue: 616.7M
- Channels: creative, influencer, social
- Advantages: scale buying power, data
Cross-sell within sexual health and hair
Cross-selling sexual health and hair leverages Hims & Hers large installed base to expand into adjacent SKUs, driving higher ARPU through bundles and upgrades while minimizing acquisition spend.
Personalization and timed offers support growth by improving conversion and retention, maintaining high share within a growing consumer health wallet.
- Installed-base expansion
- Bundles raise ARPU
- Timed personalization boosts LTV
- High share in expanding wallet
Digital health leader — 616.7M revenue, ~500M hair run-rate, huge ED & telehealth markets
Hims & Hers is a Star: FY2023 revenue 616.7M, 2024 hair run-rate ~500M, ED market >1.5B and telehealth ~$62.5B (2024). Strong LTV/CAC (payback 6–9 months), high share in DTC hair and ED, growth via cross-sell, personalization and owned pharmacy.
| Metric | 2023/24 |
|---|---|
| Revenue FY2023 | 616.7M |
| Hair run-rate 2024 | ~500M |
| ED US market | >1.5B |
What is included in the product
Detailed Word Document
BCG Matrix of Hims & Hers: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold or divest guidance and trend context.
Customizable Excel Spreadsheet
One-page BCG matrix highlighting Hims & Hers units to pinpoint growth vs pain-point divestment.
Cash Cows
OTC hair kits (topical minoxidil, shampoos)
OTC hair kits (topical minoxidil, shampoos) are mature, well-known Hims & Hers SKUs with steady repeat purchases and predictable margins; the global hair-loss treatment market was estimated at about $4.1B in 2023, underpinning stable demand. Low innovation cycles mean minimal promo beyond retention, conserving gross margin. These products generate reliable cash flow to fund newer growth bets.
Generic ED refills at scale
Generic ED refills are price-stable and margin-friendly at scale; generics account for roughly 90% of U.S. prescriptions (FDA), driving predictable unit economics.
The category is mature versus earlier hypergrowth, with steady demand and lower CAC relative to new product launches.
Auto-ship lowers service costs and smooths cash flow by increasing retention; milk volume economics while maintaining care and adherence levels.
Asynchronous consults for simple conditions
Asynchronous consults for simple conditions streamline intake and can reduce clinician time roughly 50–70% versus live visits, enabling higher clinician capacity. The telehealth market has matured with outpatient tele-visit penetration stabilizing near 15% post-pandemic, so efficiency — not growth — is the lever. High throughput, low friction workflows drive strong unit economics; continue optimizing intake, routing, templates, and tooling to squeeze margin.
Private-label derm basics
Private-label derm basics deliver steady, low-single-digit unit growth rather than breakout expansion, acting as a reliable cash cow for Hims & Hers in 2024.
Scaled house-brand SKUs drive gross margins in the 55–65% range, require limited ongoing marketing after retail placement, and help cover fixed overhead.
- Steady SKU velocity
- 55–65% gross margins
- Low sustained marketing
- Stable overhead support
Membership/auto-ship infrastructure
Hims & Hers membership/auto-ship infrastructure uses automated billing, prescription reminders, and logistics to keep churn low and cashflow predictable, monetizing an established customer base efficiently rather than driving fast top-line growth.
Small UX, pricing, and fulfillment tweaks typically yield outsized margin gains, supporting a maintain-and-harvest strategy for this cash-cow segment.
- Billing reliability: reduces involuntary churn
- Reminders + logistics: steady reorder rates
- High-margin: incremental tweaks amplify profit
- Strategy: maintain core, harvest cash
OTC hair kits: $4.1B market, 55–65% margins, 50–70% clinician time cut
OTC hair kits and private-label derm basics are mature SKUs with steady repeat purchases; global hair-loss market ~$4.1B in 2023 supports stable demand. Generics (~90% of U.S. scripts) and auto-ship lift unit economics; asynchronous consults cut clinician time ~50–70%, boosting throughput. Gross margins ~55–65% make these reliable cash cows to fund growth bets.
| Metric | Value |
|---|---|
| Hair market 2023 | $4.1B |
| Generics share (US) | ~90% |
| Clinician time cut | 50–70% |
| Gross margin | 55–65% |
What You’re Viewing Is Included
Hims & Hers Health BCG Matrix
The file you're previewing is the final Hims & Hers Health BCG Matrix you'll receive after purchase. No watermarks, no demo copy—just the fully formatted, analysis-ready report. It's crafted for strategic clarity and immediate use in planning or presentations. Buy once and download the exact same editable document, ready to share with your team.
Dogs
One-off retail-only SKUs
Single-purchase retail-only SKUs deliver low margins (around 20–25%), are hard to differentiate, and generate limited cross-sell and lifetime value, often yielding LTV:CAC well below 1. Inventory and slotting tie up cash—retail slotting fees and working capital can consume 20–30% of gross margin—while limited first-party data reduces repeat purchase rates. These SKUs are prime candidates to trim.
Broad tele-derm vs specialist leaders
Broad tele-derm acne plays face heavy price compression and crowded competition, with average visit prices reported to have fallen roughly 15% since 2020 and specialist incumbents holding premium pricing. Competing head-on with niche leaders offers limited upside as telederm growth is modest versus specialty clinics and share gains are hard to sustain. Hims & Hers’ generalist derm unit lacks commanding share and shows sluggish growth metrics. Recommend divestment or focus on narrow profitable niches (e.g., hormonal acne, follow-up maintenance).
Standalone video visits without subscription
Pay-per-visit telehealth lacks LTV and is highly price-sensitive; with 2024 short-term retention commonly under 20% and no subscription stickiness, revenue per customer remains low. Scheduling friction and elevated no-show/cancellation rates compress margins and limit repeat utilization. In a low-growth pocket these offerings typically only break even at best. Avoid heavy investment and prioritize subscription-led channels.
Generic supplements with no edge
Dogs:
Generic supplements with no edge
Undifferentiated gummies and basic vitamins in Hims & Hers face brutal competition from national CPG brands and Amazon private labels, yielding low brand premium and high discounting pressure that erodes margins and increases return risk; inventory often sits in fulfillment centers, creating a cash trap—recommended sunset or fold into subscription bundles only.- Low differentiation
- High discounting risk
- Inventory cash-trap
- Bundle or discontinue
Long-tail SKUs with sporadic demand
Dogs: Long-tail SKUs with sporadic demand add operational complexity for Hims & Hers; they neither move revenue nor market share and inflate inventory and support costs—2024 reviews of product assortment show low turnover for these SKUs and rising fulfillment overhead.
Prune the tail: rationalize SKUs based on velocity and contribution, redirect spend to high-margin, recurring-care offerings that drive subscriber growth in 2024.
- Low turnover
- High carrying & support cost
- Minimal revenue/share
- Recommendation: prune tail
Sunset low-turn supplements - 20-25% GM, LTV:CAC under 1; fold into subs
Generic supplements and long-tail SKUs deliver ~20–25% gross margin, LTV:CAC <1, SKU turnover <0.5/yr and carry 20–30% gross margin in slotting/holding costs. Heavy discounting drives ASP declines ~10–15% YoY (2022–24). Recommend sunsetting or folding into subscription bundles to free cash and focus on recurring care.
| Metric | Value (2024) |
|---|---|
| Gross margin | 20–25% |
| LTV:CAC | <1 |
| SKU turnover | <0.5/yr |
| Holding/slotting | 20–30% GM |
| ASP decline | 10–15% YoY |
Question Marks
GLP‑1 weight management programs
Explosive GLP‑1 demand positions Hims & Hers' weight‑management program as a Question Mark: US adult obesity prevalence 41.9% (CDC) and 2023–24 prescription surges create a multi‑billion‑dollar runway, but intense competition and 2023–24 supply constraints at Novo Nordisk and Eli Lilly keep share fluid. Hims is a newer entrant so market share is still forming; unit economics can be attractive if affordable sourcing and patient adherence hold, making bold investment justified if access is secured.
Women’s health expansion (birth control, menopause)
Women’s health expansion faces rising demand—global digital women’s health market reached about $4.6 billion in 2024, growing ~18% YoY—yet incumbents like Nurx and Maven hold strong share. Hims & Hers has brand permission with over 1.5 million consumers as of 2024 but needs sharper differentiation in clinical pathways and product bundling. If conversion and retention improve materially, this Question Mark can flip to a Star; without that, it risks drifting into low-growth niche status.
Mental health meds and care bundles
Category growth is robust and crowded with well-funded rivals; digital mental health startups raised >$2B in 2023 (industry reports) while about 1 in 5 US adults experience mental illness annually (CDC). Trust, continuity, and measurable outcomes drive winners and justify premium retention. If Hims & Hers demonstrates durable retention and improved outcomes, share can scale quickly. Requires focused investment and rigorous measurement of clinical and retention metrics.
International expansion
International expansion sits in Question Marks: telehealth rules vary widely across markets, slowing rollout despite a growing global telehealth market projected at about $185B by 2028; local incumbents retain meaningful share and regulatory nuance increases CAC and time-to-profitability. If regulatory pathways and distribution partners align, upside for Hims & Hers is material; pursue a test-and-learn approach before scaling.
- Regulatory variability: slows launch
- Market growth: global telehealth ~ $185B by 2028
- Local competition: high share holders
- Strategy: pilot, partner, scale if compliant
At-home diagnostics and monitoring
Rapid consumer interest in remote testing continues, with the FDA authorizing over 60 at-home diagnostic tests by 2024, yet adoption remains fragmented and Hims & Hers holds a low share amid operational complexity for specimen logistics and telehealth integration.
If tightly integrated with care plans and Rx/renewal flows, customer LTV rises materially via higher adherence and recurring revenue; pilot selectively, measure attach rates, then double down where attach exceeds target thresholds.
- Fast growth: 60+ FDA-authorized at-home tests (2024)
- Current position: low share, high ops complexity
- Value driver: tight care-plan integration boosts LTV
- Go-to-market: pilot small, scale where attach is high
GLP‑1, women's health, telehealth & 60+ FDA tests: scale when access, retention, pilots win
Question Marks: GLP‑1 ops target huge demand (US adult obesity 41.9% CDC) but supply/competition keeps share fluid; women’s health leverages 1.5M customers and $4.6B market (2024) yet needs differentiation; mental health and intl telehealth (global telehealth ~$185B by 2028) require focused pilots; 60+ FDA at‑home tests (2024) offer ops complexity but LTV upside if integrated.
| Category | 2024 metric | Key risk | Trigger to scale |
|---|---|---|---|
| GLP‑1 | 41.9% obesity | supply/competition | secured access & favorable unit economics |
| Women’s health | $4.6B market; 1.5M users | low differentiation | improved conversion/retention |
| Mental/Intl | 185B proj. telehealth (2028) | regulatory/CAC | pilot success & regulatory clarity |
| At‑home tests | 60+ FDA auth | ops complexity | high attach rates |